Neurogene (NGNE)

Executive Summary

Neurogene Inc. is a clinical-stage biotechnology company developing regulated gene therapies for rare neurological diseases using its proprietary EXACT™ transgene regulation platform. The company's lead program, NGN-401, is currently in a registrational trial for Rett syndrome, a severe genetic disorder with no approved therapies. Neurogene's EXACT platform enables dose-dependent, reversible transgene expression, potentially improving safety and efficacy over conventional gene therapies. The company also has internal manufacturing capabilities to support its pipeline. Neurogene went public via a SPAC merger in 2024 and trades under ticker NGNE. The company is well-positioned to address high unmet need in Rett syndrome, with NGN-401 as a potential first-in-class therapy. Despite early-stage pipeline, the registrational trial design and novel platform provide a clear path to value inflection.

Upcoming Catalysts (preview)

• Q4 2026NGN-401 Registrational Trial Data Readout60% success
• Q2 2027Potential BLA Submission for NGN-40150% success
• Q3 2026EXACT Platform Expansion into New Indication30% success